Atezolizumab monotherapy in Chinese patients with locally advanced or metastatic solid tumours

L. Shen,L. Zhang,X. Hu,H. Pan,T. Liu,Y. Bai,Y-C. Chen,J. Huang,T. Xu,W. Hsu,J. Shi

DOI: https://doi.org/10.1093/annonc/mdy432.006

IF: 51.769

2018-01-01

Annals of Oncology

Abstract:Background: Atezolizumab (atezo; anti–PD-L1) has proven efficacy in large global studies. To better understand the benefit of atezo in tumours that are highly prevalent in China, a basket trial was conducted in Chinese patients (pts) with locally advanced or metastatic solid tumours. Methods: This phase I study (NCT02825940) consisted of a PK phase (solid tumour) and an extension phase (HCC, EC, NPC or GC) in pts who had exhausted all available standard treatment (tx) options. Pts received 1200 mg atezo IV every 3 weeks until loss of clinical benefit. Study objectives were to evaluate PK, safety, and efficacy by investigator-assessed objective response rate (ORR), duration of response (DOR) and progression-free survival (PFS) per RECIST v1.1, as well as overall survival (OS). Results: As of 1 Apr 2018, 94 pts with median follow-up of 10.6 mo (range, 0+ to 19+) were evaluable. 85 pts (90%) received prior systemic tx for recurrent/metastatic disease. PK parameters from the PK cohort will be presented. ORR results are presented in the table. Median DOR for all responders was not reached. Among 43 pts (46%) treated beyond progression, 3 pts (2 GC, 1 PK) achieved new partial responses. The median PFS was 2.8 mo (95% CI: 1.4, 3.8) in the 94 overall pts and 2.8 mo (95% CI: 1.4, 4.4) in the 42 PD-L1+ pts. Median OS was 8.4 mo (95% CI: 6.4, 12.4) overall and 11.3 mo (95% CI: 5.6, NE) in PD-L1+ pts. All grade (Gr) tx-related adverse events (TRAE) occurred in 78 of 94 pts (83%). The most common Gr 3-4 TRAEs were hyponatremia (5%), aspartate aminotransferase (3%) and lipase increased (3%). 2 pts with EC (2%) had a Gr 5 TRAE (fistula anTable154O EfficacyPatients by cohortPooled patients by biomarker statusPK (n = 20)HCC (n = 20)EC (n = 20)NPC (n = 20)GC (n = 14)PD-L1 + (n = 42)MSI-H (n = 8)ORR,aIncludes confirmed and unconfirmed responses. EC, esophageal cancer; GC, gastric cancer; HCC, hepatocellular carcinoma; MSI-H, microsatellite instability high; NPC, nasopharyngeal carcinoma; ORR, objective response rate; PD-L1+, programmed death-ligand 1 positive; PK, pharmacokinetic; SD, stable disease. n (%)3 (15%)4 (20%)3 (15%)2 (10%)2 (14%)8 (19%)2 (25%)ORRaIncludes confirmed and unconfirmed responses. EC, esophageal cancer; GC, gastric cancer; HCC, hepatocellular carcinoma; MSI-H, microsatellite instability high; NPC, nasopharyngeal carcinoma; ORR, objective response rate; PD-L1+, programmed death-ligand 1 positive; PK, pharmacokinetic; SD, stable disease. + SD rate, n (%)9 (45%)12 (60%)8 (40%)13 (65%)8 (57%)21 (50%)4 (50%)a Includes confirmed and unconfirmed responses. EC, esophageal cancer; GC, gastric cancer; HCC, hepatocellular carcinoma; MSI-H, microsatellite instability high; NPC, nasopharyngeal carcinoma; ORR, objective response rate; PD-L1+, programmed death-ligand 1 positive; PK, pharmacokinetic; SD, stable disease. Open table in a new tab d unexplained death). Conclusions: Efficacy was seen in multiple solid tumour types, with a tolerable safety profile and a consistent PK profile in line with previous global studies. Atezo will be further studied as monotherapy and in combination with other agents in tumour types highly prevalent in China, particularly in HCC. Editorial acknowledgement: Medical writing assistance for this abstract was provided by Steffen Biechele, PhD, of Health Interactions and funded by F. Hoffmann-La Roche, Ltd. Clinical trial identification: NCT02825940. Legal entity responsible for the study: F. Hoffmann-La Roche, Ltd. Funding: F. Hoffmann-La Roche, Ltd. Disclosure: Y-C. Chen: Employment: Genentech/Roche. J. Huang, T. Xu, W. Hsu, J. Shi: Employment: Roche. All other authors have declared no conflicts of interest.